

LISTING OF CLAIMS

1-14. (Cancelled)

15. (New) A method of treatment of a host with a cellular proliferative disease, comprising contacting said host with a naphthalimide comprising an amonafide in conjunction with an antiproliferative agent comprising homoharringtonine, each in an amount sufficient to modulate said cellular proliferative disease.

16. (New) A method according to claim 1 wherein said naphthalimide is administered before the administration of said antiproliferative agent.

17. (New) A method according to claim 1 wherein said naphthalimide is administered during the administration of said antiproliferative agent.

18. (New) A method according to claim 1 wherein said naphthalimide is administered after the administration of said antiproliferative agent.

19. (New) The method according to claim 1 wherein the modulation of said disease with said naphthalimide and said antiproliferative agent is greater than that for said naphthalimide or said antiproliferative agent alone.

20. (New) The method of claim 1, wherein said cellular proliferative disease is a tumor.

21. (New) The method of claim 21, wherein said tumor is a solid tumor.

22. (New) The method according to claim 21 wherein said modulation comprises the reduction of tumor growth.

23. (New) The method according to claim 21 wherein said modulation comprises inhibition of tumor growth.

24. (New) The method according to claim 21 wherein said modulation comprises an increase in tumor volume quadrupling time.

Attorney Docket .: A-70245-2

Filed: July 31, 2003

25. (New) A composition comprising an amonafide and homoharringtonine, wherein the modulation of a cellular proliferative disease by amonafide and homoharringtonine is greater than that for amonafide or homoharringtonine alone.